Immunome (NASDAQ: IMNM) net income
Immunome reported a net loss of $212.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $293.0m. Earnings per share were −$2.43.
Immunome's best year of the last 7 was fiscal 2019. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$212.4m | — | −3,060.0% | −$2.43 |
| 2024 | −$293.0m | — | −3,240.4% | −$5.00 |
| 2023 | −$106.8m | — | −761.9% | −$5.38 |
| 2022 | −$36.9m | — | — | −$3.09 |
| 2021 | −$24.7m | — | — | −$2.14 |
| 2020 | −$17.8m | — | −1,783,700.0% | −$5.26 |
| 2019 | −$10.4m | — | −104,440.0% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Immunome net income compared with its sector
By net income for its latest fiscal year, Immunome ranks 419th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Immunome, −3,060.0%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 417th | Damora Therapeutics | −$209.8m | — |
| 418th | Disc Medicine | −$212.2m | — |
| 419th | Immunome | −$212.4m | −3,060.0% |
| 420th | Cullinan Therapeutics | −$219.9m | — |
| 421st | Vanda Pharmaceuticals | −$220.5m | −102.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Immunome
- How much did Immunome earn in fiscal 2025?
- Immunome reported a net loss of $212.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $293.0m.
- What are the earnings per share of Immunome?
- They were −$2.43 in fiscal 2025, compared with −$5.00 in fiscal 2024.
- Where does Immunome rank in its sector by net income?
- It ranks 419th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Immunome come from?
- From the annual report (Form 10-K) that Immunome files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Immunome files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Immunome: the Immunome page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.